Related Experiment Video
Updated: Mar 29, 2026
08:21
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
2.2K
Single-nucleotide polymorphisms: a perspective of cardiovascular prevention
Guilherme Brasil Grezzana1, José Luiz da Costa Vieira2, Vera Lúcia Portal3
1Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia, Porto Alegre, RS, Brazil.
Revista Da Associacao Medica Brasileira (1992)
|November 26, 2015
Summary
Single-nucleotide polymorphisms (SNPs) related to lipid metabolism influence cardiovascular risk. Lowering LDL-cholesterol (LDL-c) may reduce heart attack risk, but increasing HDL-cholesterol (HDL-c) shows no clear benefit.
Area of Science:
- Genetics and Cardiovascular Medicine
- Lipid Metabolism and Pharmacogenomics
Background:
- Cardiovascular events are linked to lipid biomarkers, but long-term studies face follow-up challenges.
- Understanding responses to hypolipidemic drugs requires further investigation.
Purpose of the Study:
- To evaluate the role of single-nucleotide polymorphisms (SNPs) in lipid metabolism.
- To determine the clinical implications of these SNPs in various scenarios.
Main Methods:
- A systematic literature search was conducted in multiple databases (Medline, Lilacs, IBECS, Cochrane).
- Studies focused on plasmatic lipid profiles, SNPs, cardiovascular outcomes, and statin effectiveness were included.
Main Results:
- Nineteen studies were analyzed from 89 identified citations.
- Low LDL-cholesterol (LDL-c) levels correlated with reduced heart attack risk.
- Increased HDL-cholesterol (HDL-c) levels did not show a similar association with reduced risk.
Conclusions:
- SNPs in lipid metabolism offer insights into cardiovascular risk.
- Understanding genetic variations can help optimize lipoprotein management for cardiovascular risk reduction.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:27Principles of Pharmacogenetics: Types of Genetic Variants
95
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95
01:05Single Nucleotide Polymorphisms-SNPs
19.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K
01:26Coronary Artery Disease IV: Preventive Measures
839
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839
01:27Pharmacogenetics of Drug Metabolism: Overview
112
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
112